anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients who were assigned to the conventional group received radial artery compression by a gauze pad folded into a cuboid shape, fastened with 3M™ Durapore™ surgical tape. The gauze pad was not impregnated with prothrombotic material. Compression was released at 3 hours to check for complications. An additional one hour of compression was applied when incomplete hemostasis or hematoma was identified.
Disclosed is a novel composition which has a function of accelerating production of collagen. The composition has high light stability and is free from side effects such as those of retinoids. Specifically disclosed is a collagen production accelerating composition which contains one or more compounds selected from the group consisting of D-aspartic acid, D-alanine, derivatives of D-aspartic acid or D-alanine and/or salts of D-aspartic acid or D-alanine. The composition may be used for the purpose of suppressing and/or improving skin conditions. The skin conditions may include but is not limited to photoaging and/or wrinkles. The composition may be used for an external preparation for the skin or food. The composition may be a type I collagen production accelerating composition.
At Day -7, all subjects will be exposed to a pre-specified range of doses of visible light on 6 areas of the back, each measuring 0.9 cm\^2 in order to evaluate their pigmentary response to visible light. The doses will be 20, 40, 80, 160, 320 and 640 J/cm\^2. At Day 0, a visual inspection will establish which subjects qualify for the remainder of the study, based on the presence or absence of pigmentation induced by visible light. Subjects who do not exhibit pigmentation at 640 J/cm\^2 or lower will not pursue the study.

Subjects who demonstrate pigmentation will move on to the next step of the study. On this same Day 0 visit, these subjects will be randomized to receive a topical antioxidant preparation on one of two halves of their back and a control on the other side. The antioxidant and control will be applied twice before the exposure to visible light is done on Day 1: 24 hours prior (Day 0) and 30 minutes prior (Day 1) exposure. On Day 1, the skin with antioxidant will be exposed to fluences of 80, 160, 320, 640, 1280 and 1920 J/cm\^2 whereas that with control will be exposed to the same lower doses as on Day -7. This will be done on a total of 12 different areas of 0.9 cm\^2 each, with six on the side with antioxidant preparation, and six on the side with control.

On Day 7±1, a visual assessment will be done of each exposed area, as well as quantitative colorimetric measurements and a research photograph. The visual assessment will consist in determination of the lowest fluence inducing visible pigmentation on each half back (with antioxidant and with control). The colorimetric measurements will be done on areas exposed to 320 and 640 J/cm\^2 to compare the pigmentation present on skin to which antioxidant was applied and on skin to which control was applied. The colorimetric assessment of adjacent unexposed skin will also be performed. At Day 0, 1 and 7 visits, subjects will also be evaluated for adverse events.
Liver failure leading to transplantation has been reported in a patient with cirrhosis and portal hypertension while receiving TRIKAFTA. Avoid use of TRIKAFTA in patients with pre-existing advanced liver disease (e.g., as evidenced by cirrhosis, portal hypertension, ascites, hepatic encephalopathy) unless the benefits are expected to outweigh the risks. If used in these patients, they should be closely monitored after the initiation of treatment [see Dosage and Administration (2.2), Adverse Reactions (6), Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].

Isolated elevations of transaminases or bilirubin have been observed in patients with CF treated with TRIKAFTA. In some instances, transaminase elevations have been associated with concomitant elevations in total bilirubin and/or international normalized ratio (INR) and have resulted in patients being hospitalized for intervention, including in patients without a history of pre-existing liver disease. 

Assessments of liver function tests (ALT, AST, and bilirubin) are recommended for all patients prior to initiating TRIKAFTA, every 3 months during the first year of treatment, and annually thereafter. In the event of significant elevations in liver function tests, e.g., ALT or AST >5 × the upper limit of normal (ULN) or ALT or AST >3 × ULN with bilirubin >2 × ULN, dosing should be interrupted, and laboratory tests closely followed until the abnormalities resolve. Following the resolution of liver function test elevations, consider the benefits and risks of resuming treatment. For patients with a history of hepatobiliary disease or liver function test elevations, more frequent monitoring should be considered [see Dosage and Administration (2.2), Adverse Reactions (6), Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].
The present study aims to evaluate the oncological outcomes of laparoscopic mCME on right-sided colon cancer. The right side of the colon was defined as the colon from cecum up to the proximal half of the transverse colon. The number of patients needs to get a 90% power is 250. Patients will be enrolled at five leading centers in South Korea. A complete information leaflet will give to the patients during the first consultation, which will correspond to the enrollment day. The preoperative, intraoperative, and postoperative period will be in complete accordance with the usual care of the center. The baseline demographics and conditions, as well as the perioperative items and the postoperative occurrences, will be recorded through a prior designed case report form. The follow-up encompasses 13 postoperative consultations: 1month, 3 months, after that every 3 months until 36 months.

The primary outcome of this study is 3-year disease-free survival. Secondary outcome measures include 3-year overall survival, the incidence of surgical complications, completeness of mCME, and distribution of metastatic lymph nodes. Review of resected surgical specimens and the operative field after completion of lymph node dissection will be done based on photographs to assess the quality if surgery.
Busulfan test dose (32 mg/m\^2) on day -9 then 130 mg/m\^2 intravenous (IV) Days -7, -6, -5, and -4 + Melphalan 70 mg/m2 IV on Days -2 and -1. Stem Cell Transplant (SCT) Day 0.
<P>PROBLEM TO BE SOLVED: To provide a modified polysaccharide, in particular a modified Neisseria meningitides serogroup A polysaccharide, which retains immunogenicity but has improved stability.  <P>SOLUTION: The modified polysaccharide, in particular the modified Neisseria meningitides serogroup A polysaccharide retains immunogenicity but has improved stability. Typically, the modified polysaccharide is prepared by reacting a capsular polysaccharide, oligosaccharide fragment thereof, with a bifunctional reagent such as CDI, followed by reaction with an amino compound such as dimethylamine. Modified polysaccharide-protein conjugates and vaccines prepared from such conjugates are also described. There is also provided a modified capsular saccharide containing a protective group in the position of a hydroxyl group in at least one monosaccharide unit of the corresponding natural capsular saccharide.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Anemia associated with lung cancer and chemotherapy is an important factor effecting patient symptoms, functional status, and overall quality of life (Groopman and Itri 1999; Langer, Choy et al. 2002). Darbepoetin alfa (Aranesp®) has demonstrated a significant effect upon ameliorating chemotherapy-induced anemia in lung cancer (Vansteenkiste, Pirker et al. 2002; Vansteenkiste, Poulsen et al. 2002). This trial is designed to evaluate the association between the treatment of anemia with darbepoetin alfa and direct electronic capture of clinical benefits in cancer-related symptoms, functional status and overall quality of life. This trial uses a secure web-based design to capture the patient-associated symptoms, functional status and quality of life. This novel secure web-based system was selected to improve the efficiency and quality of clinical data capture. If our hypothesis is correct, treatment with darbepoetin alfa will be associated with improved palliation of cancer-related symptoms, improved functional status, and result in overall benefits to the patient's health-related quality of life. The development of a web-based system to directly capture patient-related symptoms, functional status and quality of life will permit us in the future to conduct a national or international trial addressing the effects of darbepoetin alfa on these factors. If our hypothesis is incorrect, it may be that these parameters are not affected by the correction of anemia with darbepoetin alfa or the measures are not sensitive enough to detect these differences. A notable finding would be a clearly defined improvement in symptom palliation, functional status, and quality of life associated with darbepoetin alfa therapy.
The primary aim of this study is to test the efficacy of memantine, a noncompetitive NMDA receptor antagonist, in reducing early attrition and improving outcome in opioid-dependent individuals maintained on naltrexone.

This double-blind, 12-week trial will include heroin-dependent patients who completed detoxification. Participants will be randomly assigned to one of three conditions: naltrexone and placebo, naltrexone and memantine (15 mg bid), or naltrexone and memantine (30 mg bid). Naltrexone will be taken 3 times each week at the clinic, while memantine or placebo will be taken at home. In addition, twice each week patients will receive a psychosocial intervention that will include motivational interviewing and cognitive-behavioral relapse prevention. The goal of the psychosocial intervention is to improve compliance with medication and maintain abstinence. Baseline assessments will be taken and compared to those completed at study visits, which will occur 3 times each week.
No clastogenic or mutagenic effects of natalizumab were observed in the Ames test or in vitro chromosomal aberration assay in human lymphocytes. Natalizumab showed no effects in in vitro assays of α4-integrin positive human tumor line proliferation/cytotoxicity. Xenograft transplantation models in SCID and nude mice with two α4-integrin positive human tumor lines (leukemia, melanoma) demonstrated no increase in tumor growth rates or metastasis resulting from natalizumab treatment. 

In male guinea pigs administered natalizumab (0, 3, 10, or 30 mg/kg) by intravenous (IV) infusion on alternate days from 28 days prior to and continuing throughout mating (to untreated females), no effects on fertility were observed. The highest dose tested is 6 times the recommended human dose (RHD) (300 mg) on a body weight (mg/kg) basis. 

In a separate study in female guinea pigs (mated with untreated males), natalizumab (0, 3, 10, or 30 mg/kg), administered by IV infusion on alternate days from gestation day (GD) 30 of the first pregnancy through GD 30 of the second pregnancy, resulted in a decrease in pregnancy rate and number of implantations at 30 mg/kg. (Fertility parameters were assessed for the second pregnancy.) The no-effect dose for effects on female fertility (10 mg/kg) is 2 times the RHD on a body weight basis.
The inclusion of the spiritual dimension in healthcare has been a recommendation of the World Health Organization (WHO) since 1984. According to the WHO, 'spiritual' refers "to those aspects of human life relating to experiences that transcend sensory phenomena. This is not the same as 'religious', though for many people the spiritual dimension of their lives includes a religious component. The spiritual aspect of human life may be viewed as an integrating element holding together the physical, psychological and social dimensions. It is often perceived as being concerned with meaning and purpose". Today there is a growing body of scientific evidence for therapeutic relevance of the spiritual dimension in different fields of medical health care. Based on this increasing scientific evidence, medical associations such as the Royal College of Psychiatrists recommend the assessment of spiritual needs for therapeutic goals. Despite those long-standing calls and findings, these recommendations have not yet been widely implemented. Even in palliative care, patients indicate that their spiritual concerns are often inadequately addressed. Many clinicians report that they lack the required communication skills to adequately address spiritual concerns, while patients are not used to bring up their spiritual needs by themselves. As spiritual needs can only be integrated into care delivery if known to the practitioners, an explicit assessment is necessary. There are numerous instruments to assess spiritual aspects in the context of health care research - but only few to be used in a clinical context. Furthermore, there are many instruments that take into account the specific spiritual needs at the end of life in palliative care, while there are fewer established instruments in the care of chronic diseases. To close this gap, the investigators constructed and validated a new screening tool for assessing spiritual distress and resources, the Spiritual Distress and Resources Questionnaire (SDRQ) in patients with chronic pain in a previous project within the National Research Program "Smarter Health Care" (NRP 74).

The results of this NRP 74 project showed clearly: Spiritual aspects are considered as important in the context of chronic pain by health care professionals and patients alike. They could be important resources to be integrated in a multimodal pain therapy.

In this study, the investigators want to assess spiritual resources, spiritual distress and spiritual coping in patients with psychiatric disorders of the affective spectrum. To compare the results with the results of chronic pain patients, similar questionnaires as in the above mentioned study within NRP 74 will be used. Additionally, the investigators want to assess the proportion and characteristics of patients who wish spiritual aspects to be integrated in the therapeutic setting. Overall, the goal is to create knowledge to adequately address spiritual aspects in those patients who wish the integration of their spiritual needs into treatment.
Coronavirus disease 2019 (COVID-19) due to a severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection can include various systemic organ disorders including endocrinopathies and neurological manifestations. We report the case of a 65-year-old Japanese man who developed isolated adrenocorticotropic hormone (ACTH) deficiency and encephalopathy following SARS-CoV-2 infection. Two weeks after his COVID-19 diagnosis, he was emergently admitted to our hospital because of subacute-onset delirium. On admission, he presented hyponatremia (128 mEq/L) and secondary adrenal insufficiency (ACTH <1.5 pg/mL, cortisol 0.53 μg/dL). Brain imaging and laboratory examinations including SARS-CoV-2 polymerase chain reaction testing in the cerebrospinal fluid revealed no abnormalities. His consciousness level worsened despite the amelioration of hyponatremia by intravenous hydrocortisone (100 mg/day), but his neurological presentations completely resolved after three consecutive days of high-dose (400 mg/day) hydrocortisone. His encephalopathy did not deteriorate during hydrocortisone tapering. He continued 15 mg/day hydrocortisone after discharge. His encephalopathy might have developed via a disturbance of the autoimmune system, or a metabolic effect associated with adrenal insufficiency, although the time lag between the hyponatremia's improvement and the patient's neurological response to the steroid was incompatible with common cases of delirium concurrent with adrenal insufficiency. At 13 months after his hospitalization, the patient's neurological symptoms have not recurred and he has no endocrinological dysfunctions other than the remaining ACTH deficiency. A thorough consideration of the immunological and metabolic characteristics of SARS-CoV-2 is advisable when clinicians treat patients during and even after their COVID-19 disease period.
Individually titrate OTFC to a dose that provides adequate analgesia and minimizes side effects. The initial dose of OTFC to treat episodes of breakthrough cancer pain is always 200 mcg. The OTFC unit should be consumed over 15 minutes. Patients should be prescribed an initial titration supply of six 200 mcg OTFC units, thus limiting the number of units in the home during titration. Patients should use up all units before increasing to a higher dose to prevent confusion and possible overdose. 

Repeat Dosing

  1. In cases where the breakthrough pain episode is not relieved after 15 minutes after completion of the OTFC unit (30 minutes after the start of the unit), patients may take ONLY ONE additional dose using the same strength for that episode. Thus patients should take a maximum of two doses of OTFC for any episode of breakthrough pain.
  2. Patients MUST wait at least 4 hours before treating another episode of breakthrough pain with OTFC.
PURPOSE: A composition containing Bifidobacteria extract is provided to enhance the stemness of stem cells and to enhance adipose for beauty. CONSTITUTION: A composition for enhancing the stemness of adipose-derived stem cells contains 0.0001-10 wt% of Bifidobacteria extract as an active ingredient. The stem cell is human adipose-derived stem cells(hADSCs). A composition for enhancing skin cells contains 0.0001-10 wt% of extract as an active ingredient. The skin cells are keratinocyte stem cells(KSCs) or transit-amplifying cells(TA cells). The extract is prepared by culturing and crushing the bacteria with a homogenizer.
A method and system are disclosed for externally treating human blood, with the objective of reducing the functioning lymphocyte population in the blood system of a human subject. Blood is withdrawn from the subject and passed through an ultraviolet radiation field in the presence of from about 1 nanogram to 100 micrograms per ml of blood, of a dissolved photoactive agent capable of forming photo-adducts with lymphocytic- DNA, mobile cortisone receptors or antigen sites to thereby effect covalent bonding between the photoactive agent and the same, thereby inhibiting the metabolic processes of the lymphocytes or complexing them; and thereupon returning the irradiated blood to the subject. The withdrawn blood may be formed into an extracorporeal stream 18 and flowed through a treatment station 24 whereat the irradiation is effected, as for example by exposure to UV radiation source 30; and such flow process may be conducted on a continuous basis. At least portions of the treated blood may then be separated, e.g. by a continuous centrifuge 44, before returning 14 the remaining diverted blood to the subject. <IMAGE>
This study discusses the importance of minimal residual disease (MRD) detection in acute myeloid leukemia (AML) patients using liquid biopsy and next-generation sequencing (NGS). AML prognosis is based on various factors, including genetic alterations. NGS has revealed the molecular complexity of AML and helped refine risk stratification and personalized therapies. The long-term survival rates for AML patients are low, and MRD assessment is crucial in predicting prognosis. Currently, the most common methods for MRD detection are flow cytometry and quantitative PCR, but NGS is being incorporated into clinical practice due to its ability to detect genomic aberrations in the majority of AML patients. Typically, bone marrow samples are used for MRD assessment, but using peripheral blood samples or liquid biopsies would be less invasive. Leukemia originates in the bone marrow, along with the cfDNA obtained from peripheral blood. This study aimed to assess the utility of cell-free DNA (cfDNA) from peripheral blood samples for MRD detection in AML patients. A cohort of 20 AML patients was analyzed using NGS, and a correlation between MRD assessment by cfDNA and circulating tumor cells (CTCs) in paired samples was observed. Furthermore, a higher tumor signal was detected in cfDNA compared to CTCs, indicating greater sensitivity. Challenges for the application of liquid biopsy in MRD assessment were discussed, including the selection of appropriate markers and the sensitivity of certain markers. This study emphasizes the potential of liquid biopsy using cfDNA for MRD detection in AML patients and highlights the need for further research in this area.
The present invention pertains to the field of medicine, more precisely to that of pharmacology and veterinary medicine, and essentially relates to dextran-containing synthetic and biologically active substances which exhibit an antiviral activity, mainly against herpes simplex viruses. The purpose of this invention is to produce a new chemical compound having a high antiviral activity, mainly against viruses of the herpes group. In other words, this invention relates to the chemical synthesis of a biologically active substance having an antiviral action. This invention involves synthesizing a new dextran-containing compound, i.e. dextranpolyaldehyde-resorcine, of general formula (I). This invention is further detailed in the description by an instance of the method for producing this compound, by the results of its identification, by three series of experiments for determining its biological activity and its toxicity, and by two tables.
Background & objectives Vascular endothelial growth factor (VEGF) is one of the most important angiogenic factors which stimulates tumour progression induction of endothelial cell migration and division, inhibition of the apoptosis of endothelial cells, induction of serine protease activity and enhancement of vascular permeability. This study aimed to investigate the correlation of VEGF+405G/C,-7C/T and+936C/T polymorphisms with oesophageal cancer risk. Methods DNA samples of 464 subjects (231 sporadic oesophageal cancer affected individuals and 233 controls) were genotyped forVEGF+936C/T,+405G/C and-7C/T polymorphisms. VEGF+936C/T and +405G/C polymorphisms were genotyped by PCR-RFLP method whereas VEGF-7C/T polymorphism was genotyped using Amplification refractory mutation system-polymerase chain reaction (ARMS-PCR). Results CT genotype of VEGF-7C/T polymorphism was significantly associated with reduced risk of oesophageal cancer. VEGF-7C/T polymorphism was significantly associated with reduced risk of oesophageal cancer underdominant, co-dominant, over dominant and log-additive genetic models in total patients and in the female group. C+936G+405T-7 haplotype was significantly associated with decreased risk (P=0.01)of oesophageal cancer in total patients and also in the male group (P=0.02). Interpretation & conclusions In future, replication of the findings of the present study in a larger sample from different ethnic groups, along with functional analysis, may be insightful for the role of VEGFA polymorphisms in the pathogenesis of oesophageal cancer. Identification of the correlation of VEGF variants with specific therapy in oesophageal cancer may help in better selection of patients and monitoring treatment response in VEGF-therapy.